Special Message from the ORA President regarding COVID-19

Published March 16, 2020.  12:50PM Dear Members, March break is usually a time of family, travel, relaxation and welcoming signs of Spring. Instead of that, this year we are faced with an entirely […]

Read More…


ORA Position Statement on Infusion Clinics

The ORA has created a position statement on infusion clinics during the COVID-19 pandemic.  The position update may be updated over the coming weeks so please check back often. Link: ORA position on […]

Read More…


Important Announcement about the 2020 Annual Scientific Meeting

Managing concerns around COVID-19: An updated message to our community about the ORA Annual Scientific Meeting taking place April 17-19, 2020 at the Kingbridge Conference Centre Published March 12, 2020.   Last updated March […]

Read More…


Disappointing News – Official Cancellation of 2020 ORA Annual Scientific Meeting

Managing concerns around COVID-19: An updated message to our community about the ORA Annual Scientific Meeting taking place April 17-19, 2020 at the Kingbridge Conference Centre Published March 12, 2020.   Last updated March […]

Read More…


ORA & MOHLTC Partnership

The ORA has enjoyed a longstanding partnership with the MOHLTC that is beneficial to everyone in the arthritis community. Recently David Schachow, Director, Drug Programs Delivery wrote a letter to the ORA to […]

Read More…


Biosimilar Transitioning – Guidelines and Educational Resources

Here are some educational resources on biosimilar transitioning that the ORA endorses: Arthritis Consumer Experts (ACE) has produced a special biosimilars education video series, where ACE speaks to medical experts on key patient […]

Read More…


ORA Biosimilar Position Statement

The ORA published a position statement on administrative switching in 2015 and updated it again in the Fall of 2018. The full position statement is available using the link below: ORA Position on […]

Read More…


ORA Guide to Public Drug Coverage

Dr. Felix Leung has developed a comprehensive document explaining public drug coverage for your patients. Please visit this link to access: ORA Guide to Public Drug Coverage […]

Read More…


MOHLTC Announcement: LU Code for Etanercept Effective July 31, 2019

Effective July 31, 2019. The Edition No. 43 document will be posted on the Ministry’s website http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx by July 31, 2019. Erelzi (etanercept) 25mg/0.5mL, 50mg/mL PFS, Pre-Filled Autoinj (SDZ) LU Code 563 For the treatment […]

Read More…


Your Role as a Health Information Custodian – Some Facts to Share

There is considerable value in the data stored in electronic medical records (EMRs). A number of external stakeholders including pharma companies and pharmacy networks have expressed interest in exporting these data, better to […]

Read More…